Bowen Wang

Bowen Wang

Auto-generated profile, based on publicly available information

Bowen Wang

New Cornerstone Science Laboratory, School of Pharmaceutical Sciences Tsinghua University Beijing 100084 China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2024 in Trends in Biotechnology
Verified
Journal Article
Closed access
KHKezhang He
Kezhang He
QXQiaomei Xue
Qiaomei Xue
WZWei Zhou
Wei Zhou
PWPengqi Wang
Pengqi Wang
XHXiaodan Hu
Xiaodan Hu
SDSheng Ding
Sheng Ding

11 November 2025 in Advanced Science
Verified
Journal Article
Open access
PWPengqi Wang
Pengqi Wang
KHKezhang He
Kezhang He
BWBowen Wang
Bowen Wang
WZWei Zhou
Wei Zhou
YZYing Zhang
Ying Zhang
SDSheng Ding
Sheng Ding
Ferroptosis presents great potential for cancer therapy, either alone or in combination with classical therapy. However, inducing ferroptosis by targeting canonical ferroptosis suppressors that directly inhibit lipid peroxidation non‐selectively induces ferroptosis in both cancerous and normal cells, thereby limiting its therapeutic potential. In this study, it is revealed that aldolase A (ALDOA) reprograms lipid metabolism to resist ferroptosis in cancer cells and identifies ALDOA as a targetable vulnerability for ferroptosis sensitization. Cancer cells with ALDOA suppression exhibit increased susceptibility to ferroptosis—a response less obvious in normal cells. Mechanistically, ALDOA depletion induces significant accumulation of fructose 1,6‐bisphosphate in cancer cells, thereby enhancing autophagy‐dependent degradation of phospholipid‐modifying enzymes. These alterations increase the ratio of phospholipids containing pro‐ferroptotic polyunsaturated fatty acids over anti‐ferroptotic monounsaturated fatty acids, culminating in heightened ferroptosis sensitivity. Moreover, ALDOA inhibitors selectively promote ferroptosis in cancer cells, both in vitro and in vivo. Collectively, the findings reveal that ALDOA‐mediated metabolic reprogramming is a targetable vulnerability for ferroptosis sensitization in cancer.

10 October 2025 in bioRxiv
Verified
Preprint
Open access
BWBowen Wang
Bowen Wang
YZYun Zhi
Yun Zhi
PWPengqi Wang
Pengqi Wang
WGWenbo Guo
Wenbo Guo
JGJin Gu
Jin Gu
SDSheng Ding
Sheng Ding
Despite substantial advances in targeted therapies, most patients with advanced cancers ultimately relapse. This relapse is frequently seeded by drug-tolerant persister cells (DTPs), which persist as minimal residual disease (MRD) by adopting a reversible quiescent state and later reacquire proliferative capacity under ongoing treatment. To address this, we sought to convert quiescent DTPs into an irreversible, non-proliferative state by pharmacologically inducing senescence. Through large-scale chemical screening and combination optimization, we identified SAHA plus tilorone dihydrochloride (SIC) as a regimen that robustly induces senescence in melanoma DTPs and abolishes their proliferative potential in vitro . Mechanistically, SAHA relieves HDAC1-mediated repression of HMGA2, a key senescence driver, while tilorone synergistically inhibits autophagy to promote a fully senescent state. In a melanoma xenograft mouse model receiving MAPK-targeted therapy, SIC treatment significantly suppressed MRD progression. Importantly, SIC also induced robust senescence across diverse DTP models irrespective of tumor origin, mutational background, or prior treatment. Collectively, these findings provide proof-of-concept that converting DTPs from reversible quiescence to permanent senescence represents an effective strategy to prevent relapse under targeted therapy and position SIC as a broadly applicable pharmacological approach for durable control of residual disease in advanced cancers.